RG-7410

RG-7410
Clinical data
Other namesRG7410
Routes of
administration		Unspecified
Drug classTrace amine-associated receptor 1 (TAAR1) agonist
Identifiers
CAS Number

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed. Its route of administration was unspecified.

The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was under development by Hoffmann-La Roche. RG-7410 was first disclosed by January 2014 and a phase 1 trial was reported to have been completed by October 2014.

See also

References

  1. 1 2 3 4 5 6 "RG 7410". AdisInsight. 13 October 2015. Retrieved 23 October 2024.
  2. 1 2 3 "Delving into the Latest Updates on RG-7410 with Synapse". Synapse. 19 September 2024. Retrieved 23 October 2024.
  3. ↑ "Roche 2013 results" (PDF). Roche Group. London. 30 January 2014.
  4. ↑ "Pipeline summary" (PDF). Roche Group. Changes to the development pipeline Q3 2014 update